Skip to main content
. 2024 Jan 26;5(2):101393. doi: 10.1016/j.xcrm.2024.101393

Figure 2.

Figure 2

PD-L1 IC2/3 versus IC0/1 tumors are enriched in immune-related gene signatures

(A) Heatmap detailing immune-related gene signatures based on bulk RNA sequencing of pretreatment archival tumor specimens from the IMvigor130 study according to PD-L1 status (IC2/3 and IC0/1) and treatment arm.

(B) Volcano plot detailing differentially expressed genes based on bulk RNA sequencing of pretreatment archival tumor specimens from the IMvigor130 study according to PD-L1 status (IC2/3 versus IC0/1). Differential expression analysis was conducted with limma-based statistical methods and the Benjamini-Hochberg correction.

(C) Gene set enrichment analysis based on bulk RNA sequencing of pretreatment archival tumor specimens from the IMvigor130 study according to PD-L1 status (IC2/3 versus IC0/1) and treatment arm or specific platinum drug received. The hue represents the false discovery rate (FDR) significance derived from the fgsea package. Black asterisks represent FDR < 0.05.